NASDAQ:CDXS • US1920051067
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CODEXIS INC (CDXS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-11-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-11-15 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-11-04 | Benchmark | Reiterate | Hold |
| 2024-09-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-29 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-19 | Benchmark | Downgrade | Buy -> Hold |
| 2024-08-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-05-30 | Cantor Fitzgerald | Initiate | Overweight |
| 2024-05-03 | Benchmark | Reiterate | Buy -> Buy |
| 2024-02-29 | Benchmark | Upgrade | Hold -> Buy |
| 2023-11-07 | Benchmark | Downgrade | Buy -> Hold |
| 2023-11-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-09-01 | Benchmark | Reiterate | Buy -> Buy |
| 2023-08-14 | Stifel | Maintains | Buy -> Buy |
| 2023-07-21 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2023-05-09 | Benchmark | Maintains | Buy |
| 2023-05-09 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-04-17 | Piper Sandler | Maintains | Overweight |
| 2023-02-27 | HC Wainwright & Co. | Maintains | Buy |
| 2023-01-19 | Piper Sandler | Maintains | Overweight |
| 2022-11-07 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-08 | HC Wainwright & Co. | Maintains | Buy |
| 2022-07-18 | HC Wainwright & Co. | Maintains | Buy |
| 2022-07-15 | Cowen & Co. | Maintains | Outperform |
| 2022-07-15 | Piper Sandler | Maintains | Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 70.143M -49.39% | 59.345M -15.39% | 70.387M 18.61% | 75.826M 7.73% | 86.627M 14.24% | 108.03M 24.71% | 160.04M 48.14% | 213.27M 33.26% | 291.29M 36.58% | 386.28M 32.61% | 505.88M 30.96% | |
| EBITDA YoY % growth | -49.283M -87.53% | -53.408M -8.37% | -33.084M 38.05% | -37.018M -11.89% | -31.518M 14.86% | -23.562M 25.24% | -12.954M 45.02% | 1.224M 109.45% | N/A | N/A | N/A | |
| EBIT YoY % growth | -54.801M -72.87% | -58.354M -6.48% | -38.332M 34.31% | -36.972M 3.55% | -29.182M 21.07% | -10.693M 63.36% | 27.608M 358.18% | 57.105M 106.84% | 108.04M 89.20% | 163.79M 51.60% | 224.6M 37.13% | |
| Operating Margin | -78.13% | -98.33% | -54.46% | -48.76% | -33.69% | -9.90% | 17.25% | 26.78% | 37.09% | 42.40% | 44.40% | |
| EPS YoY % growth | -1.11 -141.30% | -0.90 18.92% | -0.52 42.22% | -0.41 21.54% | -0.19 52.50% | -0.06 68.42% | -0.16 -166.67% | -0.09 43.75% | 0.22 344.44% | 0.66 195.45% | 1.45 118.46% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.15 40.43% | -0.12 24.78% | -0.11 51.78% | -0.07 -164.91% | -0.13 10.96% | -0.11 6.78% | -0.09 13.46% | -0.05 28.57% |
| Revenue Q2Q % growth | 14.73M 95.28% | 16.938M 10.50% | 19.411M 125.68% | 24.714M -36.49% | 17.748M 20.49% | 19.482M 15.02% | 23.052M 18.76% | 28.356M 14.74% |
| EBITDA Q2Q % growth | -10.403M 46.07% | -8.468M 18.01% | -6.822M 54.70% | -119.34K -100.62% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.134M 45.65% | -10.234M 20.43% | -8.672M 54.24% | -5.701M -140.82% | -11.424M -2.60% | -10.2M 0.33% | -8.16M 5.90% | -4.386M 23.07% |
All data in USD
13 analysts have analysed CDXS and the average price target is 6.71 USD. This implies a price increase of 268.95% is expected in the next year compared to the current price of 1.82.
CODEXIS INC (CDXS) will report earnings on 2026-04-30.
The consensus EPS estimate for the next earnings of CODEXIS INC (CDXS) is -0.15 USD and the consensus revenue estimate is 14.73M USD.
The number of analysts covering CODEXIS INC (CDXS) is 13.